BTAI vs. ETON, CMRX, PMVP, ONCY, AFMD, QTTB, HOOK, YS, SPRO, and CLSD
Should you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include Eton Pharmaceuticals (ETON), Chimerix (CMRX), PMV Pharmaceuticals (PMVP), Oncolytics Biotech (ONCY), Affimed (AFMD), Q32 Bio (QTTB), Hookipa Pharma (HOOK), YS Biopharma (YS), Spero Therapeutics (SPRO), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical preparations" industry.
BioXcel Therapeutics (NASDAQ:BTAI) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, community ranking, institutional ownership and valuation.
30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 35.8% of BioXcel Therapeutics shares are held by insiders. Comparatively, 13.2% of Eton Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Eton Pharmaceuticals has a net margin of -2.96% compared to BioXcel Therapeutics' net margin of -12,974.86%. Eton Pharmaceuticals' return on equity of -6.21% beat BioXcel Therapeutics' return on equity.
Eton Pharmaceuticals has higher revenue and earnings than BioXcel Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.
BioXcel Therapeutics has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500.
In the previous week, BioXcel Therapeutics had 10 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 11 mentions for BioXcel Therapeutics and 1 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 1.90 beat BioXcel Therapeutics' score of 0.57 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.
BioXcel Therapeutics presently has a consensus price target of $16.86, indicating a potential upside of 561.06%. Eton Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 226.80%. Given BioXcel Therapeutics' higher probable upside, equities analysts clearly believe BioXcel Therapeutics is more favorable than Eton Pharmaceuticals.
BioXcel Therapeutics received 153 more outperform votes than Eton Pharmaceuticals when rated by MarketBeat users. Likewise, 67.05% of users gave BioXcel Therapeutics an outperform vote while only 61.94% of users gave Eton Pharmaceuticals an outperform vote.
Summary
BioXcel Therapeutics and Eton Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get BioXcel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioXcel Therapeutics Competitors List
Related Companies and Tools
